{"filing":{"accession_number":"0001213900-26-068760","cik":"0001893645","ticker":"PLRZ","company_name":"Polyrizon Ltd.","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ea0294757-6k_polyrizon.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1893645/000121390026068760/ea0294757-6k_polyrizon.htm"},"events":[{"id":12258,"run_id":10822,"accession_number":"0001213900-26-068760","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a key human performance and characterization study for NASARIX™ (PL-14), Polyrizon's lead investigational product, conducted in collaboration with a leading European university medical center. The study is designed to evaluate nasal residence time—a critical performance parameter supporting the company's FDA regulatory pathway and development strategy. For a development-stage biotech company, advancement of a lead product through human studies and regulatory milestones is material to investor assessment of progress and value.","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9062,"accession_number":"0001213900-26-068760","item_number":"EX-99.1","item_title":"ea029475701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a key human performance and characterization study for NASARIX™ (PL-14), Polyrizon's lead investigational product, conducted in collaboration with a leading European university medical center. The study is designed to evaluate nasal residence time—a critical performance parameter supporting the company's FDA regulatory pathway and development strategy. For a development-stage biotech company, advancement of a lead product through human studies and regulatory milestones is material to investor assessment of progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:31:35.684326+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9062,"accession_number":"0001213900-26-068760","item_number":"EX-99.1","item_title":"ea029475701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a key human performance and characterization study for NASARIX™ (PL-14), Polyrizon's lead investigational product, conducted in collaboration with a leading European university medical center. The study is designed to evaluate nasal residence time—a critical performance parameter supporting the company's FDA regulatory pathway and development strategy. For a development-stage biotech company, advancement of a lead product through human studies and regulatory milestones is material to investor assessment of progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:31:35.684326+00:00","company_name":"Polyrizon Ltd.","ticker":"PLRZ","filing_date":"2026-06-15"}]}